Learn more about our pneumococcal vaccine clinical trial for healthy volunteers 18 to 49 years of age.
Pneumococcal vaccines available today have been proven safe and effective, dramatically reducing rates of serious pneumococcal disease. However, while they defend against many strains of pneumococcal bacteria, they don’t protect against all.
This clinical trial will help us learn if a study vaccine called PG4 is safe and provides protection against more strains of pneumococcal bacteria than our currently available vaccine (Prevnar 20®). We will also compare 3 different batches (lots) of the study vaccine to make sure each batch is the same.
Who may participate
We’re enrolling adults who:
- Are 18 to 49 years of age
- Are generally healthy or have stable chronic conditions
- Do not have a history of a severe reaction associated with any vaccine
There are other requirements for participation that the study team can discuss with you.
Condition
Pneumococcal disease
Age
18 to 49 years
Sex
Male or Female
Medical and vaccination history
Have not received a pneumococcal vaccine after the age of 5
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
Get started — See if you may be eligible
Answer a 3-minute questionnaire.
A first step as you consider this study is to answer a 3-minute online questionnaire about your health and medical history. If your answers show the study might be a good fit for you, you may choose to be referred to a study clinic that you select.
Speak with a study representative.
If you’re interested, you will then be asked to provide your contact information for a study representative to contact you and discuss the next steps.
Confirm your eligibility.
Your answers to these questions will only be linked to you if your responses indicate that you may be eligible to participate in this study and you choose to share your contact information with the study team. Pfizer study team members and our partners will have access to reports containing aggregated data that will not be directly linked back to you. Only the study staff can determine if you meet the study’s eligibility criteria and are able to enroll in the study.
What to expect
Before joining the clinical trial, you’ll be given all the details about participation, including potential benefits and risks.
If this study is a good fit for you and you agree to take part, you will be randomly assigned to receive 1 dose of the study vaccine (PG4) from 1 of 3 batches, or a licensed pneumococcal vaccine made by Pfizer (Prevnar 20®).
The study will last about 6 months and requires 2 in-person visits and 1 phone call.
The study vaccine and study-related procedures will be provided at no cost. You’ll also be compensated for completing some study-related activities.
Length of study
6 months
Number of study visits
2 in-person visits and 1 phone call
Number of vaccine doses
1 dose
Watch a short video to learn more about pneumococcal disease
You can make a difference
Participation by people of all backgrounds is critical to developing vaccines that protect against pneumococcal disease. The greater the diversity among clinical trial participants, the more we can learn about potential vaccines and how they work for different people. Each new vaccine breakthrough helps us reach more people to prevent and reduce the spread of disease.
Frequently asked questions
You will be randomly assigned to receive the study vaccine (PG4) from 1 of 3 different batches, or a licensed pneumococcal vaccine made by Pfizer (Prevnar 20®). All participants will have a 1 in 3.5 chance of receiving the study vaccine and a 1 in 7 chance of receiving the licensed vaccine. No one, including you, your doctor, or the study team, can choose what you are assigned to receive.
No, neither you nor the study team will know what you have been assigned to receive.
As with any vaccine, local reactions at the injection site can be common – such as redness, swelling, or pain. There is also potential for other symptoms like a mild fever, headaches, muscle aches, joint aches, or fatigue. The known side effects will be further explained in the informed consent document and discussed with you by the study doctor before you join the study. If there is any new information that we learn about the study vaccine during the clinical trial, the study doctor will share that with you as well.
At the beginning of the clinical trial, the study doctor will ask you about your medical history and any medications you are taking. You will be given an electronic diary (eDiary) to complete for at least one week after your vaccination so the study team can monitor your health. You will also have your blood drawn twice. The study team will give you more information about the tests and procedures during the review of the study’s informed consent document.
Participation is your choice. You can choose to leave the clinical trial at any time for any reason, and your regular medical care will not be affected.
